News & Events

DOC

Nuremberg, Germany

June 18-21

Club Vit Meeting

Park City, Utah

July 1-4

Masters at the Wave 2009

Maui, Hawaii

July 12-15

European VitreoRetina Society Meeting

Marrakesch, Morocco

September 5-9

 

See all News & Events

Understanding AMD

Learn about the causes of wet AMD and why it's important to understand current treatment options.

NeoVista leadership

An experienced management team, dedicated venture partners — and a growing list of NeoVista accomplishments.

Innovations

NeoVista's proprietary technology makes epiretinal beta radiation therapy a potential addition to wet AMD treatment options.

CABERNET

This important clinical study is now under way; learn more about its design and key endpoints.

About Wet AMD

NeoVista, Inc., is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50.

The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Learn more about wet AMD.

Learn more about NeoVista, Inc.

Learn more about epiretinal beta radiation therapy, our innovative core technology.

Learn more about current clinical trials of NeoVista technology.

New Videos

New Multimedia Section
  • Visit our new Multimedia page, with video presentations and animated procedures available for viewing.